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Edited by Frances ShannonAbstract Erm, a member of the PEA3 group within the Ets
family of transcription factors, is expressed in murine and human
lymphocytes. Here, we show that in the human Molt4 lympho-
blastic cell line, the erm gene expression is regulated by the con-
ventional PKC (cPKC) pathway. To better characterize the
molecular mechanism by which cPKC regulates Erm transcrip-
tion in Molt4 cells, we tested proximal promoter deletions of
the human gene, and identiﬁed a speciﬁc cPKC-regulated region
between positions 420 and 115 upstream of the ﬁrst exon.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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The Ets family transcription factors have in common the
ETS-domain, an 85 amino-acid domain organized in a winged
helix-turn-helix structure and responsible for DNA-binding to
the speciﬁc core sequence GGA(A/T) [1]. These factors can be
sub-classiﬁed in 13 groups according to the amino-acid conser-
vation not only in the ETS-domain but also in other domains,
such as transactivation or protein interaction domains. The
PEA3 group is made up of three members: Pea3 (E1af,
Etv4), Er81 (Etv1) and Erm (Etv5). These three factors are
more than 95% identical in the ETS-domain, and highly con-
served in the N-terminal acidic and C-terminal transactivation
domains [2,3].
These transcription factors are involved in developmental
processes and oncogenesis [2]. For example, in the mammary
gland, their overexpression is observed in certain human breast
cancers as well as in oncogene-induced mammary tumors [4,5].
They are also expressed upon diﬀerent stages of normal mam-
mary gland development, from embryonic emergence to post-*Corresponding author. Fax: +322 555 62 57.
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extensive ductal outgrowth and branching.
Erm also plays a regulating role in the murine Th1 CD4+
lymphocytes, in which its expression is activated by a Stat4-
dependent interleukin-12 pathway [9]. In human beings, the
erm gene is strongly and preferentially expressed in phorbol
12-myristate 13-acetate (PMA) activated Th1 cells, but it is
also detectable in Th2 and naı¨ve T cells. Nevertheless, the tar-
gets and precise roles of Erm in the Th1/Th2 lymphocyte dif-
ferentiation remain unclear [10].
PMA is known to promote the protein kinase C (PKC) path-
ways. PKC is a multigene family that encodes at least 11 dis-
tinct isoforms of serine/threonine kinases [11]. Speciﬁc
isoforms play important roles in various transduction path-
ways that regulate cell growth, transformation and diﬀerentia-
tion. This family is classiﬁed into three groups, based on their
structure and co-factor requirement: 1. conventional PKCs
(cPKCs) (a, b1, b2, and c), which are activated by phorbol es-
ters like diacylglycerol (DAG) or PMA, and calcium, 2. novel
PKCs (d, e, g, h, and l), which are activated by DAG (or
PMA) but not by calcium, and 3. novel PKCs (f, i), which
are insensitive to both phorbol esters and calcium. Each of
these isoforms contains an amino-terminal regulatory domain
and a carboxy-terminal catalytic kinase domain [11].
In the present study, we identiﬁed a cPKC pathway involved
in the expression of the erm gene in lymphoblastic Molt4 cells.2. Materials and methods
2.1. Materials and chemicals
Phorbol 12-myristate 13-acetate (PMA), Bis-indolylmaleimide III
(BimIII), Apigenin, Staurosporine, Bryostatin 1, Thymeleatoxin,
Cycloheximide and Emodin were purchased from Sigma and BAP-
TA/AM, Actinomycin D and H89 from Calbiochem.
2.2. Cell lines
Lymphoblastic Molt4 and SupT1 cell lines were purchased from
ATCC, and maintained at 37 C in a humidiﬁed atmosphere of 5%
CO2. The cell culture medium, RPMI-1640 medium (Gibco), was sup-
plemented with 10% fetal bovine serum (Gibco) and non-essential ami-
no-acids (Gibco).blished by Elsevier B.V. All rights reserved.
Fig. 1. PMA upregulates Erm mRNA expression in Molt4 cells. (A)
Dose-dependent regulation of Erm. Lymphoblastic Molt4 or SupT1
6
F. TSas et al. / FEBS Letters 579 (2005) 66–70 672.3. RNA isolation and RT-PCR
Total RNA from about 2 · 106 cells was puriﬁed by the TriPure Iso-
lation Reagent (Roche). 1.5 lg of total RNA was reverse-transcribed
with random hexamers by the use of SuperScript II reverse transcrip-
tase (Invitrogen). PCRs were performed using the Taq DNA polymer-
ase (Promega) with the following speciﬁc primers for ampliﬁcation of
the erm gene: 5 0-CATGGACGGGTTTTATGATCAGCA-3 0 and 5 0-
GGCACAATAGTTGTAGAGGC-30. Brieﬂy, 200 ng of cDNAs was
submitted to 28 cycles of PCR: denaturation for 45 s at 95 C, anneal-
ing for 45 s at 57 C, and elongation for 45 s at 72 C. The reaction was
made with a ﬁnal volume of 50 ll containing 3 mM MgCl2, 0.25 mM
of each dNTP and 30 pmoles of each primer. Expression of the actin
gene was used as control and was also studied by means of the same
RT-PCR procedure using 28 PCR cycles with the following speciﬁc
primers: 5 0-GGGTCAGAATTCCTATG-3 0 and 5 0-GGTCTCAAA-
CATGATCTGGG-3 0. Actin control RT-PCRs were performed on
the same RNA products than the erm RT-PCRs. PCR products were
analyzed by electrophoresis in a 2% agarose gel.cells (2 · 10 ) were treated for 6 h with the indicated concentrations of
PMA. Total cellular mRNAs were extracted and RT-PCR analysis
was performed to examine the expression of erm. The actin mRNA
expression level was used as an internal experimentation control. (B)
Time-dependent regulation of Erm. Cells were treated with 20 ng/ml
PMA for the indicated times. RT-PCR analyses were performed as in
(A).2.4. Western blot
Polyclonal anti-Erm antiserum was obtained by immunizing mice
with puriﬁed recombinant human Erm protein overexpressed in the
bacculovirus system. Mouse anti-b-actin antibody was purchased from
Amersham. Cellular proteins were separated for 1 h on gradient 10%
SDS–PAGE at 20 mA and electroblotted onto nitrocellulose ﬁlters
for 60 min at 100 V. The blots were treated with washing solution
(5% fat-free milk, 0.1% Tween 20 in phosphate-buﬀered saline) and
incubated overnight at 4 C, with a 1:2500 dilution of mouse anti-
Erm polyclonal antibody, or 1:5000 dilution of mouse anti-b-actin
antibody. The blots were washed and incubated for 1 h at room tem-
perature, in a 1:10000 dilution of anti-mouse immunoglobulin G cou-
pled to horseradish peroxidase (Amersham). After three washes,
detection was done by enhanced chemiluminescence (RennaissanceR,
NEN) according to the manufacturers instructions.2.5. Transient transfections and luciferase assays
The erm promoter fragments were ampliﬁed by PCR (GC-rich PCR
kit, Roche) on human U2Os cell genomic DNA using the following





(pERM-0.2-Luc) or ‘‘erm+6’’ 5
0-AAAACGCGTCAGCCGCTGG-
TGCGCGGAGCG-3 0 (pERM-0.1-Luc), and the downstream
oligonucleotide ‘‘erm+95’’ 5
0-GGCCTCGAGACGCACGCGCG-
CAGCG-GGCCTGGGCGCCTG-30. PCR products were cloned into
the pGL3basic vector (Promega) using the MluI and XhoI restriction
sites present in the PCR primers, see schematic representation of these
vectors in Fig. 4A. The constructs were then sequenced as described [12].
Molt4 and SupT1 cells were transiently transfected by the DEAE-
Dextran method as previously described [13]. To evaluate the tran-
scriptional activity, cells were harvested and luciferase activity was
determined using the Luciferase Assay System (Promega). Results were
normalized with respect to the concentration in protein obtained by
means of the Bradford method (Bradford DC method, Biorad).3. Results
3.1. PMA treatment upregulates erm mRNA in Molt4 cells
We examined the level of erm mRNA in human lymphoblas-
tic Molt4 and SupT1 cells by means of the RT-PCR method.
Expression of actin mRNA was provided as an internal con-
trol. The two cell lines were treated with various doses of
PMA, a potent PKC activator. The level of erm expression is
very low in Molt-4 non-treated cells, when compared to its le-
vel in SupT1 non-treated cells. In Molt4 cells treated for 6 h,
PMA upregulated the expression of erm mRNA in a dose-
dependent manner and the maximal eﬀect was obtained from
the concentration of 2 ng/ml PMA. In contrast, no eﬀect was
observed in SupT1 cells (Fig. 1A). In Molt4 cells, this PMA-in-duced erm upregulation occurred as early as 2 h after PMA
addition and the maximal eﬀect was detected from 4 to 6 h
after (Fig. 1B). Again, 2–48 h of PMA treatment had no eﬀect
on erm expression in SupT1 cells. These results strongly sug-
gest the involvement of a PKC pathway in the transcriptional
regulation of the erm gene in Molt4 cells.
3.2. Erm mRNA is speciﬁcally upregulated through a
conventional PKC pathway
To test whether the upregulation of erm mRNA by PMA in-
volves the activation of a PKC signaling pathway, expression
of erm mRNA was analyzed in Molt4 cells treated with
PMA and speciﬁc inhibitors of diﬀerent pathways. We used
three diﬀerent PKC inhibitors – BimIII, Staurosporine and
Apigenin, as well as the PKA inhibitor H89, and the Casein
Kinase II (CK2) inhibitor Emodin. All three PKC inhibitors
(BimIII, Staurosporine and Apigenin) blocked PMA-induced
erm mRNA expression in the Molt4 cells. PKA and CK2
inhibitors did not aﬀect the level of erm messenger. The inhib-
itors tested did not have any apparent eﬀect in the SupT1 cells
(data not shown). In order to more precisely identify the PKC
involved in erm regulation, Molt4 cells were treated with the
PKC pathway activators Bryostatin 1 (Bryo) and Thymelea-
toxin (Ttox). These latter also activated ermmRNA expression
in Molt4 cells. We evaluated by densitometry analysis on
agarose gels of RT-PCR products that the levels of PMA-,
Bryo- and Ttox-induced Erm expression are, respectively,
2.4-, 2.3- and 2.8-fold higher than that of the control one.
As observed for PMA, the PKC inhibitor BimIII inhibited
the Bryo- and the Ttox-induced eﬀect. The level of Erm expres-
sion in cells treated with BimIII in the presence or the absence
of one of the three PKC activators varied between 10% and
50% under the level obtained on untreated cells (Fig. 2B).
The fact that Bryo and Ttox are able to activate erm expression
suggests that the classical PKC pathway (a, b1, b2 and c iso-
forms) is involved in this regulation. More particularly, Ttox
is speciﬁc of a, b1 and c isoforms [14]. In order to conﬁrm
the involvement of the cPKC sub-family in erm expression,
we also tested the BAPTA/AM, which is an intracellular
Ca2+ chelator. In fact, only the cPKCs require Ca2+ [15]. We
Fig. 3. PMA regulates Erm at the transcriptional level in Molt4 cells.
(A) Actinomycin D treatment. Cells were treated with the indicated
doses of Actinomycin D (ActD) for 30 min and then with or without
PMA (20 ng/ml) for 4 h. (B) Cycloheximide treatment. Cells were
treated for 30 min with or without 20 lg/ml of Cycloheximide alone
and then for 4 h with or without 20 ng/ml of PMA. Erm and actin
mRNAs were determined by RT-PCR analysis as described in Fig. 1.
Fig. 2. Erm mRNA expression is dependent on the PKC pathway in
Molt4 cells. (A) Eﬀect of PKC inhibitors. 2 · 106 Molt4 cells were pre-
treated for 1 h with the PKC inhibitors Bis-indolylmaleimide III
(BimIII) (10 lM), Staurosporine (250 nM) and Apigenin (50 lM), or
with the intracellular Ca2+ chelator BAPTA/AM (25 lM), PKA
inhibitor H89 (25 lM), and CK2 inhibitor Emodin (100 lM). 0 or 20
ng/ml PMA was then added for 4 h. (B) Eﬀect of the PKC pathway
activators. Molt4 cells were pre-treated with or without the PKC
inhibitor BimIII (10 lM) for 1 h, and then treated with PMA (20 ng/
ml), Bryostatin 1 (Bryo: 100 nM) or Thymeleatoxin (Ttox: 100 nM)
alone or in combination with BimIII, for 4 h. Erm and actin mRNAs
were determined by RT-PCR analysis as described in Fig. 1. (C)
Western Blot analysis. Fifty lg of total proteins from untreated and
PMA-treated Molt4 cells was separated on SDS–PAGE, and the blot
was incubated with either the mouse anti-Erm polyclonal antibody, or
the mouse anti-b-actin antibody, followed by an anti-mouse immuno-
globulin G (Amersham).
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Ca2+ accessibilities, since BAPTA/AM can reverse PMA-in-
duced erm expression in Molt4 cells (Fig. 2A). The PKC
signaling pathway involved is thus Ca2+-dependent and
PMA-responsive, thus ﬁtting with the conventional sub-family
of PKC properties. Western blot analysis with an anti-Erm
antibody showed that Erm protein is, as erm mRNA, upregu-
lated by the PKC pathway, whereas b-actin protein is not
aﬀected by this treatment (Fig. 2C).
3.3. Erm expression is regulated by PMA at the transcriptional
level
To assess whether RNA synthesis is required for the PMA-
induced upregulation of erm mRNA, the lymphoblastic Molt4
cell line was co-treated with PMA and Actinomycin D, a DNA-
primed RNA polymerase inhibitor. As shown in Fig. 3A, the
erm mRNA upregulation by PMA was inhibited by Actinomy-
cin D, even at concentrations as low as 1 lg/ml, suggesting the
involvement of a transcriptional mechanism in the regulation
process. To test whether a protein translation step is necessary
for erm upregulation by PMA, Molt4 cells were co-treated with
PMA and Cycloheximide – a protein translation inhibitor – andthe latter compound had no eﬀect on PMA-induced erm regu-
lation (Fig. 3B). We can thus conclude that protein translation
is not required for PMA-induced erm mRNA. In SupT1 cells,
neither Actinomycin D nor cycloheximide treatment inﬂuenced
erm mRNA expression (data not shown).
3.4. Identiﬁcation of the PMA-dependent erm promoter region
To more precisely identify the mechanism involved in the
PMA-induced erm transcription, we analyzed the proximal
promoter region of the human erm gene [16]. Two non-coding
alternatively spliced exons (1a and 1b) were previously identi-
ﬁed upstream of the ATG-containing exon, but exon 1a ap-
peared to be used in most of the cases [16]. Thus, two
promoter constructs upstream of exon 1a (0.5 kbp: 420 to
+95, 0.2 kbp: 115 to +95) and one region, taken as control,
in exon 1a (0.1 kbp: +6 to +95) were cloned into the pGL3ba-
sic vector. The pGL3basic, pERM-0.5-Luc, pERM-0.2-Luc
and pERM-0.1-Luc plasmids were transiently transfected into
Molt4 and SupT1 for 24 h. As expected, the pERM-0.1-Luc
plasmid displayed a rather null transcriptional activity. In con-
trast, both pERM-0.5-Luc and pERM-0.2-Luc were transcrip-
tionally active in Molt4 and SupT1 cells (Fig. 4A). The cells
were then treated for 4 h with or without PMA. In Molt4 cells,
although the pGL3basic, the pERM-0.2-Luc and the pERM-
0.1-Luc reporter plasmids were not regulated by PMA, the
pERM-0.5-Luc plasmid was 2.5-fold induced following PMA
treatment. These data suggest the presence of a responsive ele-
ment for a cPKC targeted transcription factor within the 420
to 115 erm promoter region. As illustrated in Fig. 4C, the
PMA-induced eﬀect on the transcriptional activity of the
pERM-0.5-Luc reporter plasmid is also observed in Molt4
cells with the cPKC pathway activator Ttox; whereas on the
pERM-0.2-Luc reporter plasmid this latter compound had
no eﬀect.4. Discussion
In the present study, we have analyzed the transcriptional
mechanisms involved in speciﬁc upregulation of the Ets tran-
scription factor Erm after PMA activation in cultured human
lymphoblastic Molt4 cells. Although erm is weakly expressed































































































































Fig. 4. The 500 bp promoter of the human Erm gene is regulated by the PKC pathway in Molt4 cells. (A) Schematic representation of the human
erm promoter regions studied. These promoter regions were cloned upstream of the luciferase reporter gene into the pGL3basic plasmid. Molt4 or
SupT1 cells (3 · 106) were transfected with 250 ng of pERM-0.5-Luc, pERM-0.2-Luc, or pERM-0.1-Luc. Twenty-four hours after transfection, cells
were harvested for luciferase activity and protein measurements. Results for each construct were normalized using protein concentration and are
expressed as luciferase activity. The data represent means ± S.E.M. of three independent experiments. (B) Molt4 or SupT1 cells were transfected with
250 ng of pERM-0.5-Luc, pERM-0.2-Luc, or pERM-0.1-Luc. Twenty-four hours after transfection, cells were incubated with or without PMA (20
ng/ml) for 4 h. The luciferase activities were obtained as in (A) and are presented relative to the corresponding promoter construct control without
PMA (=100%). (C) Molt4 cells were transfected with 250 ng of pERM-0.5-Luc or pERM-0.2-Luc reporter plasmid. Twenty-four hours after
transfection, cells were treated for 4 h with PMA (20 ng/ml) or Thymeleatoxin (Ttox: 100 nM). The luciferase activities were obtained as in (A); 100%
corresponding to the non-treated cells.
F. TSas et al. / FEBS Letters 579 (2005) 66–70 69[17], PMA/ionomycine-activated Th1 cells overexpress it [10].
Moreover, during murine Th1/Th2 commitment, the tran-
scription factors Erm and T-bet are selectively expressed in
Th1 cells [9]. We could thus hypothesize that this transcrip-
tion factor plays a key role in normal T cell diﬀerentiation.
In leukemia, as indicated by our previous data, Erm is ex-
pressed in the following cell lines: the CEM, Molt4 and Jur-
kat lymphoblastic cells, the HEL erythroleukemia cells, the
U937 promonocytic cells and the Dami megakaryocytic cells
[17]. Although erm is expressed in both cell lines tested in the
present study, i.e., SupT1 and Molt4, we showed that erm is
transcriptionally upregulated by phorbol esters in the latter
only. Absence of erm-transcriptional regulation by PMA in
SupT1 cells is probably due to the relatively high level of
erm transcript in these cells, when compared to that in Molt4
cells. Since the phorbol ester PMA acts through the PKCpathway [18,19], and using speciﬁc inhibitors such as emodin
and H89, we were able to exclude the involvement of the
CK2 and PKA pathways, respectively, in the PMA-induced
erm expression in Molt4 cells. The data obtained on erm
expression, with either the speciﬁc intracellular Ca2+ chelator
BAPTA/AM [15] or the speciﬁc PKC activators Bryostatin 1
and Thymeleatoxin [14], permit us to more precisely deter-
mine which of the 11 PKCs are involved in this process,
i.e., the a, b1 and c isoforms.
Other ets genes are also transcriptionally regulated by the
PKC pathway. This is the case for ese-1 and ese-3, which are
transcriptionally upregulated by PMA in bronchial epithelial
cells. Interestingly, in these cells, PMA induced SPRR1B gene
expression by upregulating these two Ets transcription factors
which directly bind to the SPRR1B promoter [20]. Moreover,
in vascular smooth muscle cells, PMA induced a dose-
70 F. TSas et al. / FEBS Letters 579 (2005) 66–70dependent ets-1 mRNA expression [21]. Many other genes are
also transcriptionally regulated by PMA. For example, treat-
ment of mouse primary keratinocyte cultures with PMA re-
duced DNA synthesis and sequentially induced an
upregulation of p21Cip1/WAF1, hairless and involucrin
mRNAs in a time-dependent fashion [22]. Moreover, PMA in-
duces MMP-9 expression via NF-jB activation, and mutation
of its promoter at the NF-jB site completely abolishes PMA-
induced transcriptional activity [23].
In this paper, we provided evidence that the erm gene is reg-
ulated by the cPKC pathway in Molt4 cells at the transcrip-
tional level. In fact, PMA-induced erm mRNA expression is
blocked by Actinomycin D. This result led us to identify more
precisely the promoter region involved in PMA-induced erm
regulation. We took advantage of the previous work mapping
the human erm gene and its regulatory regions [16]. We focused
our interest on the region upstream of the ﬁrst exon 1A and
identiﬁed a functional cPKC sensitive region between positions
420 and 115. Interestingly, putative binding sites for AP1,
MEF2, NFY, CAAT, CREB, Myb and EKLF transcription
factors were identiﬁed in this region. For example, the AP1
binding site at position 357 could be a target of this pathway.
In fact, the AP-1 family of proteins has previously been shown
to be involved in PMA-gene regulation. In the myeloid leuke-
mic U937 cell line, the expression of hMSH2 MMR protein is
regulated by PKC activity [24]. In NK cells, transcription of
the 2B4 (CD244) gene is regulated by PMA and mutation of
the AP1 binding site induces a loss of PMA induction [25].
However, our preliminary results indicated that mutation of
the putative AP1 site of the human erm gene did not aﬀect
PMA-regulation (data not shown). In K562 hematopoietic
cells, transcriptional regulation by PMA of the human GM3
synthase (hST3 Gal V) gene is dependent of the CREB respon-
sive site within the promoter [26]. Similarly, in Jurkat cells,
expression of the human MAT2A gene is also induced by
PMA through the transcription factor c-Myb [27]. Identiﬁca-
tion of the transcription factors that are responsible for PKC-
induced Erm transcription in Molt-4 cells would be of help to
explain the absence of response in PMA-treated SupT1 cells.
We thus focus our interest on these two latter diﬀerent sites;
and subsequently the identiﬁcation of the targeted genes after
PMA-activation in Molt-4 cells would be an important step
in the understanding of the function of this transcription factor.Acknowledgments: FT is a recipient of a ‘‘FRIA’’ grant (Fonds Na-
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